Connect with us


Patrys Limited Announces Publication of PAT-DX1 Preclinical Data in JCI – Insight – BioSpace

Patrys Limited, a therapeutic antibody development company, has announced the publication of preclinical data for its therapeutic…



Series of preclinical studies demonstrate the therapeutic potential of PAT-DX1, a first-in-class, synthetically lethal DNA-binding antibody in primary brain cancers and brain metastases.MELBOURNE–(BUSINESS WIRE)– Patrys Limited (ASX:PAB), a therapeutic…

Click here to view the original article.

Continue Reading

You might also like ...

Article feature image
What is a COVID-19 vaccine ‘breakthrough’ case? – ABC News
New Zealand’s bowel-cancer screening program saves lives: minister – Xinhua | – Xinhua